CREATE Medicines Demonstrates Complete B Cell Depletion and Repeatable Dosing in Non-human Primates with In Vivo CAR-T Platform
PR Newswire —
Industry-leading non-human primate (NHP) data validates CREATE's differentiated receptor design, targeted RNA-LNP platform, and ability to repeat dose Clinical entry planned H2 2026 CAMBRIDGE, Mass., Feb. 2, 2026 /PRNewswire/ -- CREATE Medicines, Inc. ("CREATE"), a clinical-stage...